NDA 021660 · Bristol-Myers
Abraxane
Paclitaxel · Intravenous · Microtubule Inhibitor
OrphanLast checked: Nov 20, 2026Latest source record: Aug 25, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jan 7, 2005
Approved uses
5
Original approval plus efficacy supplements
Registered trials
5,298
1,055 Phase 3, 888 recruiting
FAERS reports
101,114
97,345 serious, 16,524 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE MYELOSUPPRESSION • Do not administer ABRAXANE therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm 3 [see Contraindications (4) ]. • Monitor for neutropenia, which may be severe and result in infection or sepsis [see Warnings and Precautions (5.1 , 5.3) ]. • Perform frequent complete blood cell counts on all patients receiving ABRAXANE [see Warnings and Precautions (5.1 , 5.3) ]. WARNING: SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning . • Do not administer ABRAXANE therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm 3 . ( 4 ) • Monitor for neutropenia, which may be severe and result in infection or sepsis. ( 5.1 , 5.3 ) • Perform frequent complete blood cell counts on all patients receiving ABRAXANE. ( 5.1 , 5.3 )
What it is approved for
From the label in effect Oct 31, 2022.
ABRAXANE is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ( 1.1 ) • Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) • Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. ( 1.3 ) 1.1 Metastatic Breast Cancer ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. 1.2 Non-Small Cell Lung Cancer ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. 1.3 Adenocarcinoma of the Pancreas ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Mechanism: ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 6, 2019 Supplement 46 · Efficacy · priority review LabelLetterPediatric Medical Review
- Sep 6, 2013 Supplement 37 · Efficacy · priority review OrphanLabelReviewLetter
- Oct 11, 2012 Supplement 31 · Efficacy LabelReviewLetter
- Feb 15, 2007 Supplement 10 · Efficacy LabelReviewLetter
- Jan 7, 2005 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelPediatric Written RequestPediatric Amendment 1
1 products under this application
- ABRAXANE · PACLITAXEL 100MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Paclitaxel" as an intervention, any sponsor and status, largest first.
- The Dual Antiplatelet Therapy Study (DAPT Study)Pivotal-lookingCompleted
Baim Institute for Clinical ResearchAcademic, hospital or other
NCT00977938 · 25,682 participants · Start Oct 2009 · Primary completion Jun 2014
Drug: Placebo & Aspirin; Clopidogrel & Aspirin, Prasugrel & Aspirin · For: Coronary Artery Disease
Sites: Fairhope, Alabama; Gilbert, Arizona; Phoenix, Arizona · 256 sites in all
- ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00490139 · 8,381 participants · Start May 16, 2007 · Primary completion Dec 6, 2013
Drug: Lapatinib; Trastuzumab · For: Neoplasms, Breast
Sites: Mobile, Alabama; Anchorage, Alaska; Tucson, Arizona · 924 sites in all
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00433511 · 4,994 participants · Start Nov 2, 2007 · Primary completion Jan 7, 2014
Drug: Bevacizumab; Cyclophosphamide and 2 more · For: Breast Adenocarcinoma
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 842 sites in all
- ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerPivotal-lookingCompleted
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT01779206 · 4,936 participants (planned) · Start May 2012 · Primary completion Sep 2019
Drug: Epirubicin; Cyclophosphamide and 2 more · For: Breast Cancer
Sites: Munich, Germany; Mönchengladbach, Germany
- Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast CancerPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT00093795 · 4,894 participants · Start Oct 2004 · Primary completion Mar 2012
Drug: Cyclophosphamide; Docetaxel and 3 more · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Stuart, Florida · 12 sites in all
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01358877 · 4,804 participants · Start Nov 8, 2011 · Primary completion Dec 19, 2016
Drug: 5-Fluorouracil; Carboplatin and 8 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Everett, California; Greenbrae, California · 546 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea5,613
- neutropenia5,563
- off label use5,388
- diarrhoea5,265
- dyspnoea5,190
- anaemia4,891
- death4,509
- malignant neoplasm progression4,508
- fatigue4,309
- neuropathy peripheral4,095
- pyrexia3,984
- disease progression3,938
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 626 |
| 2005 | 853 |
| 2006 | 665 |
| 2007 | 687 |
| 2008 | 946 |
| 2009 | 1,096 |
| 2010 | 1,148 |
| 2011 | 1,956 |
| 2012 | 2,607 |
| 2013 | 2,742 |
| 2014 | 2,623 |
| 2015 | 3,931 |
| 2016 | 4,464 |
| 2017 | 4,527 |
| 2018 | 6,481 |
| 2019 | 6,495 |
| 2020 | 6,372 |
| 2021 | 6,872 |
| 2022 | 8,471 |
| 2023 | 8,823 |
| 2024 | 10,274 |
| 2025 | 10,694 |
| 2026 | 7,760 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Abraxane (Paclitaxel Protein-Bound)
2024 spending
$7.2M
Beneficiaries
234
984 claims
Per beneficiary
$30,613
$1,528.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,792,937 |
| 2021 | $9,534,885 |
| 2022 | $6,230,058 |
| 2023 | $7,462,298 |
| 2024 | $7,163,424 |
Part B: Abraxane* (Paclitaxel Protein-Bound*) · HCPCS J9264
2024 spending
$263M
Beneficiaries
13,324
82,225 claims
Per beneficiary
$19,747
2024 ASP limit $13.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $339,499,319 |
| 2021 | $333,905,537 |
| 2022 | $324,160,700 |
| 2023 | $283,940,703 |
| 2024 | $263,102,491 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD, Ervin T, Arena FP, et al. · N Engl J Med 2013 · Clinical Trial, Phase III, Multicenter Study
- Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Olawaiye AB, Gladieff L, O'Malley DM, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Mok TS, Wu YL, Thongprasert S, et al. · N Engl J Med 2009 · Clinical Trial, Phase III, Comparative Study
- Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
Powell MA, Bjørge L, Willmott L, et al. · Ann Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Schmid P, Adams S, Rugo HS, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.
Rao S, Samalin-Scalzi E, Evesque L, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.